Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter
- 1 February 1997
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 29 (2), 385-390
- https://doi.org/10.1016/s0735-1097(96)00506-2
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- To prolong refractoriness or to delay conduction (or both)?European Heart Journal, 1992
- Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: Observations on the role of trial design and implications of drug-related mortalityAmerican Heart Journal, 1992
- Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutterThe American Journal of Cardiology, 1992
- Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.Circulation, 1990
- Rate-Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK-68,798Journal of Cardiovascular Pharmacology, 1990
- Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.The Journal of general physiology, 1990
- When is QT prolongation antiarrhythmic and when is it proarrhythmic?The American Journal of Cardiology, 1989
- Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus RhythmAnnals of Internal Medicine, 1987
- Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observationsAmerican Heart Journal, 1985
- A Comparison of Some Approximate Confidence Intervals for the Binomial ParameterJournal of the American Statistical Association, 1979